Yoshihiko Tachi

6PUBLICATIONS
15CO-AUTHORS
Tumour immunologyPharmacogenomicsCardiology (incl. cardiovascular diseases)Predictive and prognostic markersMedical biochemistry - lipids
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 15, 2026
Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.

|Oct 15, 2019
Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.

Hidenori Toyoda, Masanori Atsukawa, Tsunamasa Watanabe

|Mar 16, 2019
The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.

Masanori Atsukawa, Akihito Tsubota, Hidenori Toyoda

|Nov 29, 2018
Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antivirals.

Yoshihiko Tachi, Takanori Hirai, Yuko Kojima

|Feb 28, 2018
Impact of myosteatosis on skeletal muscle volume loss in patients with chronic liver disease.

Yoshihiko Tachi, Akihiro Kozuka, Takanori Hirai

|May 31, 2017
Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response.

Yoshihiko Tachi, Takanori Hirai, Yuko Kojima

Pageof 1

Frequent Collaborators

3 joint publications

Yoji Ishizu

2 joint publications

Kazuhiko Hayashi

2 joint publications

Masanori Atsukawa

1 joint publications

Yasuhito Tanaka